Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL2698481 | 0.99 | PTGES (0.76) | PTGESALOX5 | |
| SCHEMBL2695970 | 0.97 | PTGES (0.80) | PTGESALOX5 | |
| Hydrochloric Acid SCHEMBL2695960 | 0.97 | PTGES (0.79) | PTGESALOX5 | |
| Oxalic Acid SCHEMBL2696945 | 0.95 | PTGES (0.77) | PTGESALOX5 | |
| Trifluoroacetic Acid SCHEMBL2697819 | 0.95 | PTGES (0.76) | PTGESALOX5 | |
| SCHEMBL2698810 | 0.92 | PTGES (0.79) | PTGESALOX5 | |
| Citric Acid SCHEMBL2698823 | 0.91 | PTGES (0.70) | PTGESALOX5 | |
| SCHEMBL5522676 | 0.90 | PTGES (0.68) | PTGES | |
| SCHEMBL2696806 | 0.88 | PTGES (0.80) | PTGESALOX5 | |
| SCHEMBL2698743 | 0.88 | PTGES (0.65) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | claimed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | claimed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | PTGES 1/4885ALOX5 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.